PL1976886T3 - Środki i metody do leczenia chorób nowotworowych - Google Patents
Środki i metody do leczenia chorób nowotworowychInfo
- Publication number
- PL1976886T3 PL1976886T3 PL06818912T PL06818912T PL1976886T3 PL 1976886 T3 PL1976886 T3 PL 1976886T3 PL 06818912 T PL06818912 T PL 06818912T PL 06818912 T PL06818912 T PL 06818912T PL 1976886 T3 PL1976886 T3 PL 1976886T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- methods
- tumorous diseases
- tumorous
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05027606 | 2005-12-16 | ||
| EP06004144 | 2006-03-01 | ||
| PCT/EP2006/011466 WO2007068354A1 (en) | 2005-12-16 | 2006-11-29 | Means and methods for the treatment of tumorous diseases |
| EP06818912.5A EP1976886B1 (en) | 2005-12-16 | 2006-11-29 | Means and methods for the treatment of tumorous diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1976886T3 true PL1976886T3 (pl) | 2015-06-30 |
Family
ID=37944802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06818912T PL1976886T3 (pl) | 2005-12-16 | 2006-11-29 | Środki i metody do leczenia chorób nowotworowych |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US8007796B2 (pl) |
| EP (1) | EP1976886B1 (pl) |
| JP (2) | JP5442998B2 (pl) |
| AU (1) | AU2006326727A1 (pl) |
| CA (1) | CA2633594C (pl) |
| CY (1) | CY1116041T1 (pl) |
| DK (1) | DK1976886T3 (pl) |
| ES (1) | ES2532124T3 (pl) |
| HK (1) | HK1116202A1 (pl) |
| HR (1) | HRP20150175T1 (pl) |
| PL (1) | PL1976886T3 (pl) |
| PT (1) | PT1976886E (pl) |
| RS (1) | RS53905B1 (pl) |
| RU (1) | RU2008129080A (pl) |
| SI (1) | SI1976886T1 (pl) |
| WO (1) | WO2007068354A1 (pl) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1874821T3 (da) | 2005-04-26 | 2013-07-08 | Trion Pharma Gmbh | Kombination af antistoffer med glykokortikoider til behandling af kræft |
| CA2633594C (en) * | 2005-12-16 | 2021-10-26 | Micromet Ag | Means and methods for the treatment of tumorous diseases |
| PL2059536T3 (pl) | 2006-08-14 | 2014-07-31 | Xencor Inc | Zoptymalizowane przeciwciała ukierunkowane na CD19 |
| PL2344539T3 (pl) * | 2008-11-07 | 2015-07-31 | Amgen Res Munich Gmbh | Leczenie pediatrycznej ostrej białaczki limfoblastycznej |
| PL2982696T3 (pl) | 2008-11-07 | 2019-08-30 | Amgen Research (Munich) Gmbh | Leczenie ostrej białaczki limfoblastycznej |
| KR101841781B1 (ko) | 2009-10-27 | 2018-03-23 | 암젠 리서치 (뮌헨) 게엠베하 | ＣＤ１９ｘＣＤ３ 이중특이적 항체를 투여하는 투약 용법 |
| US8796420B2 (en) | 2009-12-31 | 2014-08-05 | Avidbiotics Corp. | Non-natural MIC proteins |
| US8658765B2 (en) | 2009-12-31 | 2014-02-25 | Avidbiotics Corp. | Non-natural MIC proteins |
| NZ609201A (en) | 2010-10-27 | 2015-01-30 | Amgen Res Munich Gmbh | Means and methods for treating dlbcl |
| EP3228315B1 (en) * | 2010-11-10 | 2020-11-25 | Amgen Research (Munich) GmbH | Prevention of adverse effects caused by cd3 specific binding domains |
| US9249217B2 (en) | 2010-12-03 | 2016-02-02 | Secretary, DHHS | Bispecific EGFRvIII x CD3 antibody engaging molecules |
| WO2012146394A1 (en) | 2011-04-28 | 2012-11-01 | Amgen Research (Munich) Gmbh | Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| JO3529B1 (ar) | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
| US9486475B2 (en) | 2013-02-08 | 2016-11-08 | Amgen Research (Munich) Gmbh | PPS for the prevention of potential adverse effects caused by CD3 specific binding domains |
| ES2960807T3 (es) | 2013-10-11 | 2024-03-06 | Us Health | Anticuerpos contra TEM8 y su uso |
| WO2015103549A1 (en) | 2014-01-03 | 2015-07-09 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
| PT3531133T (pt) | 2014-05-30 | 2023-11-07 | Amgen Inc | Estratificação de risco de pacientes de leucemia linfoblástica aguda do precursor b |
| US10160795B2 (en) | 2014-11-14 | 2018-12-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to Ebola virus glycoprotein and their use |
| KR102376244B1 (ko) * | 2014-12-24 | 2022-03-21 | 오토러스 리미티드 | 세포 |
| CA2977687C (en) | 2015-02-24 | 2024-02-13 | Hwai Wen Chang | Conditionally active proteins |
| KR20170140180A (ko) | 2015-02-24 | 2017-12-20 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 중동 호흡기 증후군 코로나 바이러스 면역원, 항체 및 그 용도 |
| SI3271389T1 (sl) | 2015-03-20 | 2020-09-30 | The United States Of America, As Represented By The Secretary Department Of Health And Human Services | Nevtralizirajoča protitelesa proti GP120 in njihova uporaba |
| CA2992306A1 (en) | 2015-08-28 | 2017-03-09 | Amunix Operating Inc. | Chimeric polypeptide assembly and methods of making and using the same |
| AU2016335750B2 (en) | 2015-10-07 | 2023-05-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia |
| CA3003878A1 (en) | 2015-11-03 | 2017-05-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 gp41 and their use |
| WO2017192589A1 (en) | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
| EP3478321A4 (en) | 2016-06-30 | 2020-04-22 | Oncorus, Inc. | PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES |
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| WO2018148660A1 (en) | 2017-02-10 | 2018-08-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
| CA3235295A1 (en) | 2017-02-20 | 2018-08-23 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| WO2019133847A1 (en) * | 2017-12-29 | 2019-07-04 | Oncorus, Inc. | Oncolytic viral delivery of therapeutic polypeptides |
| EP3724223A1 (en) | 2018-01-02 | 2020-10-21 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Neutralizing antibodies to ebola virus glycoprotein and their use |
| US11884733B2 (en) | 2018-02-08 | 2024-01-30 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
| CA3091437A1 (en) | 2018-02-21 | 2019-08-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
| US20220089694A1 (en) | 2018-12-20 | 2022-03-24 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof |
| WO2020221792A1 (en) | 2019-04-30 | 2020-11-05 | Amgen Research (Munich) Gmbh | Means and methods of treating burkitt lymphoma or leukemia |
| EP3962523A2 (en) | 2019-05-03 | 2022-03-09 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
| BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
| US20230085439A1 (en) | 2019-05-21 | 2023-03-16 | University Of Georgia Research Foundation, Inc. | Antibodies that bind human metapneumovirus fusion protein and their use |
| MX2022000174A (es) | 2019-07-02 | 2022-05-20 | Us Health | Anticuerpos monoclonales que se enlazan a egfrviii y sus usos. |
| US20230032087A1 (en) * | 2019-12-11 | 2023-02-02 | Cullinan Oncology, Inc. | Anti-serum albumin antibodies |
| IL293725A (en) * | 2019-12-11 | 2022-08-01 | Cullinan Oncology Inc | Anti-cd19 antibodies and multispecific binding proteins |
| US20230093169A1 (en) * | 2020-01-22 | 2023-03-23 | Amgen Research (Munch) Gmbh | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
| KR20220167276A (ko) | 2020-03-10 | 2022-12-20 | 매사추세츠 인스티튜트 오브 테크놀로지 | NPM1c-양성 암의 면역치료를 위한 조성물 및 방법 |
| CA3182445A1 (en) | 2020-06-11 | 2021-12-16 | Francisco Leon | Methods and compositions for preventing type 1 diabetes |
| WO2022132904A1 (en) | 2020-12-17 | 2022-06-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies targeting sars-cov-2 |
| MX2023009244A (es) | 2021-02-09 | 2023-09-11 | Us Health | Anticuerpos contra la proteina espicular de coronavirus. |
| WO2022173689A1 (en) | 2021-02-09 | 2022-08-18 | University Of Georgia Research Foundation, Inc. | Human monoclonal antibodies against pneumococcal antigens |
| WO2023044272A1 (en) | 2021-09-17 | 2023-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies |
| WO2023154824A1 (en) | 2022-02-10 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies that broadly target coronaviruses |
| WO2023192881A1 (en) | 2022-03-28 | 2023-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 env and their use |
| WO2024030829A1 (en) | 2022-08-01 | 2024-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind to the underside of influenza viral neuraminidase |
| WO2024054822A1 (en) | 2022-09-07 | 2024-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Engineered sars-cov-2 antibodies with increased neutralization breadth |
| WO2024064826A1 (en) | 2022-09-22 | 2024-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use |
| WO2024137381A1 (en) | 2022-12-19 | 2024-06-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies for treating sars-cov-2 infection |
| WO2024138151A1 (en) | 2022-12-22 | 2024-06-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ebolavirus (sudan and zaire) antibodies from non-human primates and human vaccinees |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19725586C2 (de) * | 1997-06-17 | 1999-06-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper |
| CZ302070B6 (cs) * | 1998-04-21 | 2010-09-29 | Micromet Ag | Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto |
| TW200408407A (en) * | 2001-11-30 | 2004-06-01 | Dana Farber Cancer Inst Inc | Methods and compositions for modulating the immune system and uses thereof |
| JP2007501021A (ja) * | 2003-05-30 | 2007-01-25 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 遺伝子操作された定常領域を含む、抗体および融合タンパク質 |
| EP1629012B1 (en) * | 2003-05-31 | 2018-11-28 | Amgen Research (Munich) GmbH | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| AU2004283850C1 (en) | 2003-10-16 | 2011-11-03 | Amgen Research (Munich) Gmbh | Multispecific deimmunized CD3-binders |
| DK1874821T3 (da) | 2005-04-26 | 2013-07-08 | Trion Pharma Gmbh | Kombination af antistoffer med glykokortikoider til behandling af kræft |
| CA2633594C (en) * | 2005-12-16 | 2021-10-26 | Micromet Ag | Means and methods for the treatment of tumorous diseases |
| PL2982696T3 (pl) * | 2008-11-07 | 2019-08-30 | Amgen Research (Munich) Gmbh | Leczenie ostrej białaczki limfoblastycznej |
| CN114829401A (zh) * | 2019-09-27 | 2022-07-29 | 南京金斯瑞生物科技有限公司 | 抗vhh域抗体及其用途 |
-
2006
- 2006-11-29 CA CA2633594A patent/CA2633594C/en active Active
- 2006-11-29 RS RS20150179A patent/RS53905B1/en unknown
- 2006-11-29 RU RU2008129080/13A patent/RU2008129080A/ru not_active Application Discontinuation
- 2006-11-29 SI SI200631893T patent/SI1976886T1/sl unknown
- 2006-11-29 JP JP2008544796A patent/JP5442998B2/ja active Active
- 2006-11-29 EP EP06818912.5A patent/EP1976886B1/en active Active
- 2006-11-29 PL PL06818912T patent/PL1976886T3/pl unknown
- 2006-11-29 AU AU2006326727A patent/AU2006326727A1/en not_active Abandoned
- 2006-11-29 PT PT06818912T patent/PT1976886E/pt unknown
- 2006-11-29 DK DK06818912T patent/DK1976886T3/en active
- 2006-11-29 WO PCT/EP2006/011466 patent/WO2007068354A1/en active Application Filing
- 2006-11-29 ES ES06818912.5T patent/ES2532124T3/es active Active
- 2006-11-29 US US12/095,951 patent/US8007796B2/en active Active
-
2008
- 2008-10-24 HK HK08111723.3A patent/HK1116202A1/xx unknown
-
2011
- 2011-08-26 US US13/219,120 patent/US11154617B2/en active Active
-
2013
- 2013-09-26 JP JP2013200055A patent/JP5834056B2/ja active Active
-
2015
- 2015-02-16 HR HRP20150175TT patent/HRP20150175T1/hr unknown
- 2015-02-25 CY CY20151100194T patent/CY1116041T1/el unknown
-
2021
- 2021-09-21 US US17/480,504 patent/US20220088196A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20130095103A1 (en) | 2013-04-18 |
| SI1976886T1 (sl) | 2015-03-31 |
| RU2008129080A (ru) | 2010-01-27 |
| US20090291072A1 (en) | 2009-11-26 |
| WO2007068354A1 (en) | 2007-06-21 |
| US8007796B2 (en) | 2011-08-30 |
| CA2633594A1 (en) | 2007-06-21 |
| JP2014028840A (ja) | 2014-02-13 |
| PT1976886E (pt) | 2015-03-09 |
| JP5442998B2 (ja) | 2014-03-19 |
| HRP20150175T1 (en) | 2015-03-27 |
| ES2532124T3 (es) | 2015-03-24 |
| JP5834056B2 (ja) | 2015-12-16 |
| RS53905B1 (en) | 2015-08-31 |
| WO2007068354A8 (en) | 2007-08-09 |
| EP1976886B1 (en) | 2014-12-17 |
| US20220088196A1 (en) | 2022-03-24 |
| CA2633594C (en) | 2021-10-26 |
| US11154617B2 (en) | 2021-10-26 |
| CY1116041T1 (el) | 2017-01-25 |
| HK1116202A1 (en) | 2008-12-19 |
| EP1976886A1 (en) | 2008-10-08 |
| AU2006326727A1 (en) | 2007-06-21 |
| JP2009519257A (ja) | 2009-05-14 |
| DK1976886T3 (en) | 2015-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150175T1 (en) | Means and methods for the treatment of tumorous diseases | |
| IL227841A0 (en) | Dihydropyridinones for the treatment of cancer | |
| EP1968607A4 (en) | TREATMENT OF CANCER AND OTHER DISEASES | |
| IL181305A0 (en) | Combinations for the treatment of diseases involving cell proliferation | |
| EP1811844A4 (en) | METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
| EP1814909A4 (en) | USE OF AIMP2DX2 FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
| IL177490A0 (en) | Methods for the treatment of tinnitus induced by cochlear excitotoxicity | |
| IL184934A0 (en) | 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases | |
| HK1171972A1 (zh) | 治療疾病的方法和產品 | |
| PT1881824E (pt) | Utilização de triglicéridos docosaexaenóicos para o tratamento de doenças tumorais | |
| HK1164767A1 (en) | Compounds and methods for the treatment of cancer | |
| GB0523961D0 (en) | The treatment of ophthalmic diseases | |
| ZA200806095B (en) | Means and methods for the treatment of tumorous diseases | |
| IL191887A0 (en) | Method for the diagnosis and treatment of cardiovascular diseases | |
| GB0523964D0 (en) | The treatment of ophthalmic diseases | |
| EP1846013A4 (en) | TREATMENT OF SKIN DISEASES | |
| IL185900A0 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| EP1807108A4 (en) | METHOD FOR TREATING AND PREVENTING DISEASES OF BIOLOGICAL LINES | |
| ZA200606780B (en) | Compounds for the treatment of diseases | |
| ZA200706159B (en) | Compositions and methods for the diagnosis and treatment of tumor | |
| IL175611A0 (en) | Combinations for the treatment of proliferative diseases | |
| GB0523962D0 (en) | The treatment of ophthalmic diseases | |
| GB0523965D0 (en) | The treatment of ophthalmic diseases | |
| GB0407710D0 (en) | Treatment of diseases | |
| GB0504202D0 (en) | Method of treating skin diseases |